ClinicalTrials.gg
CompletedNCT04876404Updated Oct 26, 2024

Somatotopy in Parkinson's Disease

An observational study in Parkinson Disease, sponsored by Pacific Parkinson's Research Centre. Completed at 1 site in Canada. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Pacific Parkinson's Research Centre · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Enrollment
34th of 41
30 · median 315
Started
2021
with 19 others
Observational
41 of 253
12 open now
Registered
190th of 253
by date
Lead sponsor
7 of 253
Pacific Parkinson's Research Centre

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 34th largest by enrollment of the 41 observational ones that give a count, is one of 20 that started in 2021, is one of 41 observational ones, and was the 190th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

This study aims to assess changes in connections within the brain in Parkinson's disease (PD). We will invite up to 10 people with PD to participate in this study and complete several brain scans using PET (Positron Emission Tomography) and fMRI (functional Magnetic Resonance Imaging) on the Hybrid PET/MRI scanner. We will also invite 10 participants without PD to complete the same scans for comparison. "Somatotopy" refers to how areas of the brain are organized according to the body part they affect. The striatum is the brain region that coordinates complex thinking and movement. Plasticity refers to changes in connections within the brain, which can happen to make up for changes that are related to PD. In this study we will use PET and fMRI imaging together to investigate changes in the striatum in people affected by Parkinson's disease. The hybrid PET/MR scanner allows us to perform simultaneous PET and MRI measurements to investigate this.

Read the detailed description

Purpose

The current investigation aims to study the altered striatal plasticity in early stage PD versus healthy controls to delineate the functional reorganization of dopaminergic projections in PD neurodegeneration. Analysis will be initially restricted to early PD, when compensatory mechanisms are likely compensating for deficits arising from dopamine deficiency. The use of hybrid PET-MRI imaging will allow for the simultaneous assessment of patterns of striatal activation and functional connectivity, as well as dopamine release induced by a variety of cognitive and motor tasks. In the future, depending upon the findings of this study, we will examine the effects of disease progression on segregation of striatal function. Altered plasticity is likely to contribute to clinical progression of disease and to disease and treatment related complications, thus this investigation may help advance the development of more effective PD treatment measures.

This investigation is intended as a pilot study. We currently do not have data on which to base a power analysis for sample size, however based on our previous experience using a double or triple bolus [11C] raclopride techniques, a sample size of 10 individuals per study group is adequate to detect between-group differences in dopamine release using a single bolus technique. Previous investigations we will be referencing in our study have similarly relied on small sample sizes to obtain their data.

We are specifically interested in tracking functional changes within the brain in early PD, as this is when compensatory mechanisms are still compensating for deficits arising from dopamine deficiency. Thus for the purposes of this investigation we would like to focus on early PD, with the potential to follow the PD cohort in a longitudinal fashion in future investigations, to assess progressive loss of segregation over time.

Hypotheses

  1. In healthy subjects, there will be segregation of striatal activation as measured by cerebral blood flow determined by BOLD fMRI, as well as striatal dopamine release determined using simultaneous [11C]raclopride PET, according to body site (motor activation) and task type (motor vs. cognitive vs. reward)
  2. In patients with PD, this segregation will be lost in a progressive fashion, in which caudal and dorsal striatal activation and dopamine release are lost first, with these functions shifted to progressively more rostral and ventral regions of the striatum.

Research Design

This is a cross-sectional study on 20 subjects (10 healthy control, 10 PD), involving 2-3 visits per subject to the Pacific Parkinson's Research Centre in UBC, Vancouver, BC. Each study participant will undergo 4 separate scans, 2 scans per day.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People with Parkinson's Disease and those without.

Eligibility criteria

Parkinson's Disease Individuals

Inclusion Criteria:

i. Recently diagnosed with early stage Parkinson's Disease (within 5 years of diagnosis) ii. Between the ages of 50 to 85 iii. Written obtained from subject and ability for subject to comply with the requirements of the study

Healthy Control Individuals

Inclusion Criteria:

i. Healthy male between the ages of 50 and 85 ii. Healthy female between the ages of 50 and 85 iii. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Exclusion Criteria (All Individuals):

i. Current or past major psychiatric disorders (e.g. depression, anxiety disorders) or other major neurological disease ii. Current or past substance use problems iii. Serious head injury with loss of consciousness for ≥ 5 minutes iv. Fear of enclosed, confined spaces v. Pregnant or breastfeeding vi. Presence of active, recent, or repeated cancer vii. Unstable/undiagnosed medical conditions viii. Certain medications or conditions may impact the ability to participate and these will be discussed on a case by case basis with the study team.

ix. Weight of more 158 kg x. Inability to remain still during the scans. xi. People for whom MRI is :

  • People with a non-MRI safe intrauterine device (IUD);
  • Machinist or Metalworkers;
  • Cardiac pacemaker, wires or defibrillator;
  • Past injury where a piece of metal lodged in your eye or orbit;
  • Ferromagnetic aneurysm clip;
  • Artificial heart valve;
  • Brain aneurysm clip;
  • Electrical stimulator for nerves or bones or brains;
  • Ear or eye implant;
  • Implanted drug infusion pump;
  • Coil, catheter, or filter in any blood vessel;
  • Orthopaedic hardware (artificial joint, plate, screws);
  • Other metallic prostheses;
  • Shrapnel, bullets, or other metal fragments;
  • Surgery (brain or otherwise), tattoos or injection into a join in the last 6 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Parkinson's Disease

    Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)

    Diagnostic Test: PET/MR Imaging

  • Healthy Controls

    Healthy control individuals with no neurological or mood disorders.

    Diagnostic Test: PET/MR Imaging

Interventions

  • Diagnostic testPET/MR Imaging

    The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.

    Also known as: Positron Emission Tomography and Magnetic Resonance Imaging

06

What researchers measure

Primary outcomes

  1. Striatal Dopamine Release

    \[11C\]raclopride PET

    Time frame: Baseline

  2. Striatal Activation

    BOLD fMRI

    Time frame: Baseline

07

Study locations

1 site
  • UBC Pacific Parkinson's Research Centre
    Vancouver, British Columbia, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Nov 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 6, 2021
StartActual
Jan 25, 2021
Primary completionActual
Nov 27, 2023
CompletionActual
Aug 1, 2024
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04876404
Lead sponsor
Pacific Parkinson's Research Centre
Responsible party
A. Jon Stoessl (Professor & Head of Neurology, Pacific Parkinson's Research Centre) — Principal investigator
First posted
May 6, 2021
Start date
Jan 25, 2021
Primary completion
Nov 27, 2023
Completion
Aug 1, 2024
Last update
Oct 26, 2024

Study contacts

Jess McKenzie
study director · Pacific Parkinson's Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion